Pembrolizumab-associated Neuronopathy with Improved Lower Limb Somatosensory Evoked Potential After Intravenous Methylprednisolone Treatment

DOI DOI Web Site PubMed 12 References Open Access
  • Tachiyama Keisuke
    Department of Clinical Neuroscience and Therapeutics, Hiroshima University Hospital, Japan
  • Naito Hiroyuki
    Department of Clinical Neuroscience and Therapeutics, Hiroshima University Hospital, Japan
  • Nakamori Masahiro
    Department of Clinical Neuroscience and Therapeutics, Hiroshima University Hospital, Japan
  • Aoki Shiro
    Department of Clinical Neuroscience and Therapeutics, Hiroshima University Hospital, Japan
  • Maruyama Hirofumi
    Department of Clinical Neuroscience and Therapeutics, Hiroshima University Hospital, Japan

Bibliographic Information

Other Title
  • Pembrolizumab-associated Neuronopathy with Improved Lower Limb Somatosensory Evoked Potential After Intravenous Methylprednisolone Treatment: A Case Report

Description

<p>Cases of neuronopathy associated with immune checkpoint inhibitors (ICIs) have rarely been reported. We herein report a case of ICI-associated neuronopathy. A 54-year-old man underwent chemotherapy for right maxillary sinus cancer. Two months after pembrolizumab treatment, diarrhea, worsening of abnormal sensations, and severe ataxia of the lower limbs were observed. Somatosensory evoked potentials (SEPs) with tibial nerve stimulation showed disappearance of the N21 waveform. A colonic biopsy suggested ICI-associated colitis. Based on these findings, the patient was diagnosed with ICI-associated neuronopathy. Clinical symptoms and SEP findings improved markedly after two courses of intravenous methylprednisolone. </p>

Journal

  • Internal Medicine

    Internal Medicine 64 (9), 1408-1411, 2025-05-01

    The Japanese Society of Internal Medicine

References(12)*help

See more

Keywords

Details 詳細情報について

Report a problem

Back to top